Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Operating Leases (2020 - 2025)

Pulse Biosciences has reported Operating Leases over the past 6 years, most recently at $6.4 million for Q3 2025.

  • Quarterly results put Operating Leases at $6.4 million for Q3 2025, down 23.86% from a year ago — trailing twelve months through Sep 2025 was $6.4 million (down 23.86% YoY), and the annual figure for FY2024 was $7.5 million, down 17.51%.
  • Operating Leases for Q3 2025 was $6.4 million at Pulse Biosciences, down from $8.2 million in the prior quarter.
  • Over the last five years, Operating Leases for PLSE hit a ceiling of $10.6 million in Q1 2021 and a floor of $6.4 million in Q3 2025.
  • Median Operating Leases over the past 5 years was $8.9 million (2024), compared with a mean of $8.8 million.
  • Peak annual rise in Operating Leases hit 58.92% in 2021, while the deepest fall reached 25.23% in 2021.
  • Pulse Biosciences' Operating Leases stood at $8.1 million in 2021, then rose by 13.08% to $9.1 million in 2022, then changed by 0.0% to $9.1 million in 2023, then decreased by 17.51% to $7.5 million in 2024, then fell by 15.54% to $6.4 million in 2025.
  • The last three reported values for Operating Leases were $6.4 million (Q3 2025), $8.2 million (Q2 2025), and $7.2 million (Q1 2025) per Business Quant data.